IL-2, approved by the Food and Drug Administration (FDA) for metastatic kidney cancer and for metastatic melanoma (3, 11) acts by stimulating the proliferation of T cells, cytotoxic T lymphocytes (CTL) specific to tumours, NK cells and possibly intratumor lymphocytes (2). Here, IL2 is linked to neoplasm.